Latest Articles

Publication Date
All News Scientific
Will GDHG stock benefit from AI adoption - Quarterly Trade Report & High Accuracy Swing Entry Alerts - Fundação Cultural do Pará

Will GDHG stock benefit from AI adoption - Quarterly Trade Report & High Accuracy Swing Entry Alerts Fundação Cultural do Pará

Published: Oct. 28, 2025, 8:30 p.m.
Read Full Article
Defining standards for endometriosis follow-up and improvement of care - Endometriosis.org

Defining standards for endometriosis follow-up and improvement of care Endometriosis.org

Published: Oct. 28, 2025, 3:38 p.m.
Read Full Article
Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health - MSN

Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health MSN

Published: Oct. 24, 2025, 5:25 p.m.
Read Full Article
KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer - Indian Pharma Post

KEYTRUDA + LENVIMA shows durable 5-year survival benefit in advanced endometrial cancer Indian Pharma Post

Published: Oct. 22, 2025, 5:03 p.m.
Read Full Article
NSW women to benefit from next stage of Women's Health Package - Department of the Prime Minister and Cabinet

NSW women to benefit from next stage of Women's Health Package Department of the Prime Minister and Cabinet

Published: Oct. 22, 2025, noon
Read Full Article
Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health - The Daily Galaxy

Not Only Women Menstruate: Mice Now Have Periods—and It Could Redefine Reproductive Health The Daily Galaxy

Published: Oct. 22, 2025, 10:45 a.m.
Read Full Article
NSW Women To Benefit From Next Stage Of Women's Health Package - Mirage News

NSW Women To Benefit From Next Stage Of Women's Health Package Mirage News

Published: Oct. 22, 2025, 12:27 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - The AI Journal

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen The AI Journal

Published: Oct. 18, 2025, 10:28 a.m.
Read Full Article
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen - Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen Business Wire

Published: Oct. 18, 2025, 10 a.m.
Read Full Article
Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients - Labroots

Long-Term Benefit of Adjuvant Therapy for Endometrial Cancer Patients Labroots

Published: Oct. 16, 2025, 10 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!